A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
11/2004
11/30/2004	US6825226 Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
11/30/2004	US6825219 Substituted benzimidazole compounds
11/30/2004	US6825217 Heterocyclic amines such as 4-(3'-thienyl)-alpha, alpha, 1-trimethyl-4-piperidinemethanol and/or prodrugs, used as analgesics for prophylaxis of neuropathic pain
11/30/2004	US6825207 Anticancer agents
11/30/2004	US6825204 N-substituted 3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
11/30/2004	US6825200 Substituted dipeptides having nos inhibiting activity
11/30/2004	US6825197 Cyclic GMP-specific phosphodiesterase inhibitors
11/30/2004	US6825194 Hexacyclic compounds
11/30/2004	US6825193 Heterocyclic amines such as 4-(3,4-dichlorophenyl)-2-(2-(4-methylpiperazin-1-yl)-benzylidene) -thiomorpholin-3-one, used as antiserotonine agents
11/30/2004	US6825190 Protein kinase inhibitors and uses thereof
11/30/2004	US6825186 Method and compositions for treating atheroma, tumors and other neoplastic tissue
11/30/2004	US6825185 Improving the cardiovascular profile of a cox-2 selective inhibitor by administering with 3-hydroxy-3- methylglutaryl coenzyme a, an antiplatelet agent, a thrombin inhibitor or a thromboxane inhibitor
11/30/2004	US6825166 Molecular conjugates for use in treatment of cancer
11/30/2004	US6825008 Expressed ligand—vascular intercellular signalling molecule
11/30/2004	US6825007 Therapeutic and diagnostic methods and compositions based on Jagged/Notch proteins and nucleic acids
11/30/2004	US6824978 Regulation of endogenous gene expression in cells using zinc finger proteins
11/30/2004	US6824782 Chemical modification of single chain polypeptides by means of covalent attachment of strands of polyethylene glycol to single chain polypeptide binding molecules that have three dimensional folding and binding ability
11/30/2004	US6824773 TWEAK receptor
11/30/2004	CA2468118A1 Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering rna precursors enabling the formation and function of small interfering rna in vivo and in vitro
11/30/2004	CA2298245C Matrix controlled release device
11/25/2004	WO2004101803A2 Process for producing anticancer agent ll-d45042
11/25/2004	WO2004101786A1 TRANSFORMING GROWTH FACTOR-β RESPONSE ELEMENT DECOYS AND METHODS BASED THEREON
11/25/2004	WO2004101780A2 Heparanase-derived peptides for vaccination of tumor patients
11/25/2004	WO2004101777A1 A recombinant virus comprising an intact tumor-therapeutic antibody with human costant regions and the use thereof
11/25/2004	WO2004101570A1 Sulfur-containing naphthoylimide derivatives
11/25/2004	WO2004101564A1 Pyrimidine derivatives possessing cell-cycle inhibitory activity
11/25/2004	WO2004101545A1 Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors
11/25/2004	WO2004101529A1 Nitrogenous heterocyclic compound and medical use thereof
11/25/2004	WO2004101526A1 Polymorphous crystal of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-qunolinecarboxamide and method for preparation thereof
11/25/2004	WO2004101506A1 Glyoxalase inhibitors
11/25/2004	WO2004100991A1 Use of endothelin-1 antagonists for improving cancer therapy
11/25/2004	WO2004100977A1 Inhibition of tumor cell proliferation by foxm1b inhibitors
11/25/2004	WO2004100976A1 Klotho protein, anti-klotho protein antibody and use thereof
11/25/2004	WO2004100972A1 Preventive and/or remedy for diseases accompanied by tissue destruction
11/25/2004	WO2004100961A1 Sulfate group transferase inhibitor
11/25/2004	WO2004100953A1 Combination of irinotecan and revimid for the treating multiple myeloma
11/25/2004	WO2004100873A2 Compounds, compositions, and methods
11/25/2004	WO2004091637A3 System capable of treating and defining various diseases using stem cells
11/25/2004	WO2004089356A3 Targeted bone marrow protection agents
11/25/2004	WO2004078123A3 Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
11/25/2004	WO2004069133A3 N-monoacylated o-phenylenediamines as anti -cancer agents
11/25/2004	WO2004062609A3 Pyrimidine derivatives as il-8 receptor antagonists
11/25/2004	WO2004054498A3 Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
11/25/2004	WO2003086280A3 Immunostimulatory g,u-containing oligoribonucleotides
11/25/2004	WO2003070197A3 RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/25/2004	US20040237127 Composition and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis and abnormal cell proliferation
11/25/2004	US20040236147 Integrin antagonist; antiinflammatory agents; antiarthritic agents; inflammatory bowel disease; lupus; multiple sclerosis; asthma; psoriasis;antidiabetic agents; cardiovascular disorders
11/25/2004	US20040236135 Preparation and use of alpha-keto phosphonates
11/25/2004	US20040236123 Flavanoid dimers or trimers, formed by oligomerization, then etherifying, esterifying or glycosylating to obtain drugs used as anticarcinogenic agents
11/25/2004	US20040236111 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin
11/25/2004	US20040236102 Enzyme inhibitor for treating a non-insulin dependent diabetes mellitus; 3-Amino-4-(3,4-difluorophenyl)butanoyl]-4-[2-({3-[(methylsulfonyl)amino]-phenyl}-amino)-2-oxoethyl]piperazin-2-yl}acetic acid
11/25/2004	US20040236080 Particularly having antibody-dependent cell-mediated cytotoxicity activity or complement-dependent cytotoxicity activity, used for treating cancer
11/25/2004	US20040236076 Polyclonal IgY compound from eggs of transgenic SPF-chickens with constant regions of human IgG and additionally consist of at least one signal and/or active agent and/or booster molecule; for treating noninfectious inflammations, infectious diseases, clotting disorders, autoimmune diseases and cancer
11/25/2004	US20040235962 Conformationally restricted polyamine analogs as disease therapies
11/25/2004	US20040235944 Novel pseudolaric acid-b derivatives, their preparation and pharmaceutical compositions
11/25/2004	US20040235943 Triptolide derivatives for modulation of apoptosis and immunosuppression
11/25/2004	US20040235941 Dimer digallate compositions
11/25/2004	US20040235938 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
11/25/2004	US20040235930 Indole derivatives and their use for the treatment of osteoporosis amongst other applications
11/25/2004	US20040235929 Antiestrogenic and antitumorigenic activities; cancer
11/25/2004	US20040235919 Useful in treating cell proliferative disorders associated with an altered cell cycle dependent kinase activity; cancer, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders
11/25/2004	US20040235909 substituted bis/thiohydrazide amide compound; synergistic effect with taxol or taxotere, anticancer agents, side effect reduction
11/25/2004	US20040235896 Certain azacycloalkyl substituted acetic acid derivatives
11/25/2004	US20040235880 2-(9-Chloro-3-methyl-4oxo-5H-isoxazolo[4,3-c]quinolin-5-yl)-pyridine, optionally substituted in the 6 positionof the pyridine ring; coadministering with vincristine, epirubicin, daunorubucin, doxorubicin, or etoposide to reduce the severity of MRP1 derived drug resistance
11/25/2004	US20040235876 4,5-Disubstituted-2-aminopyrimidines
11/25/2004	US20040235875 Tyrosine kinase inhibitors
11/25/2004	US20040235868 Purine derivatives having, in particular, anti-proliferative properties and their biological uses
11/25/2004	US20040235864 Jun kinase inhibitors
11/25/2004	US20040235862 Protein kinase inhibitors
11/25/2004	US20040235858 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
11/25/2004	US20040235854 1H-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1 antagonistic activity
11/25/2004	US20040235848 Phenylalanine derivatives
11/25/2004	US20040235846 Administering substituted nicotinamides and nicotinamide analogs for therapy of disorder responsive to the induction of apoptosis in an animal; anti-cancer agents
11/25/2004	US20040235845 Use of phosphodiesterase iv inhibitors
11/25/2004	US20040235843 For therapy of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy
11/25/2004	US20040235838 Use of 2-alkoxyphenol-substituted imidazotriazinones
11/25/2004	US20040235834 For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders
11/25/2004	US20040235830 Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases
11/25/2004	US20040235829 Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
11/25/2004	US20040235828 For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases
11/25/2004	US20040235826 Tyrosine kinase ihnibitors
11/25/2004	US20040235825 Administering compounds such as N-[4-[2-[2-(1-naphthyl)propanoylamino]phenyl]butanoyl]-(3,5-dimethylisoxazol-4-yl)sulfonamide for prophylaxis and therapy of pain, allodynia, hyperalgesia, pruritus, urticaria, atopic dermatitis, contact dermatitis, allergic conjunctivitis, asthma, rhinitis, sneeze
11/25/2004	US20040235818 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
11/25/2004	US20040235816 Administering compounds such as 1-benzhydryl-3-[(methylsulfonyl)(phenyl)methylene]azetidine for therapy of schizophrenia, Parkinson's disease, and Alzeimer's disease
11/25/2004	US20040235815 Vanadium compounds for treating cancer
11/25/2004	US20040235814 Administering compounds such as 1-[1-methylene-4-(bromo-methylene)phenylene]-4,8,11-tris(diethoxyphosphoryl-1,4,8,11-tetraazacyclotetra-decane to modulate a chemokine receptor
11/25/2004	US20040235808 Administering compounds such as 17 beta -[4-(dimethylamino)-benzoyloxy]-androst-4-en-3-one for modulating a function mediated by the androgen receptor in a tissue selective manner
11/25/2004	US20040235796 For therapy of proliferative disease
11/25/2004	US20040235792 For inhibiting urokinase in therapy of disease
11/25/2004	US20040235790 Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
11/25/2004	US20040235786 Highly purified antiendotoxin compound
11/25/2004	US20040235785 Potentiator of antitumoral agents in the treatment of cancer
11/25/2004	US20040235783 Pharmaceutical compositions for the treatment of tumor diseases
11/25/2004	US20040235776 Use of inhibitors for the treatment of RTK-hyperfunction-induced disorders, particularly cancer
11/25/2004	US20040235767 Synergistic mixture comprises cell adhesion molecule or a mammalian expression vector containing DNA; gene therapy; antitumor agents
11/25/2004	US20040235765 Administering as antitumor or anticarcinogenic agent; interference RNA
11/25/2004	US20040235764 Methods of inhibiting expression of a target gene in mammalian cells
11/25/2004	US20040235757 Anticarcinogenic and antimetastasis agents; leukemia or Hodgkin's disease.
11/25/2004	US20040235755 Modulating glycolysis enzyme complex/M2-PK and/or by inhibiting transaminases and/or separating the binding of the mitochondrial malate dehydrogenase to p36 protein
11/25/2004	US20040235748 Agents for preventing postoperative recurrence of premenopausal breast cancer

1 ... 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 ... 2211